At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Pegylated Interferon Alfa-2b +1 morebiological
Likely dose
Pegylated Interferon Alfa-2b 6 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia
In Brief
A Phase 2 clinical trial evaluating Pegylated Interferon Alfa-2b for Melanoma. Completed, enrolled 33 participants.
Detailed Summary
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionMar 2016
TodayJul 2026
First PostedJun 4, 2014
Enrollment StartAug 19, 2014
Primary CompletionMar 21, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.1 years ago
Interventions
Pegylated Interferon Alfa-2bbiological
6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
Pegylated Interferon Alfa-2bbiological
3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)